ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Scynexis Inc

Scynexis Inc (SCYX)

1.47
0.045
(3.16%)
Closed March 28 04:00PM
1.51
0.04
(2.72%)
After Hours: 05:41PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.51
Bid
1.45
Ask
1.55
Volume
184,086
1.42 Day's Range 1.52
1.35 52 Week Range 3.87
Market Cap
Previous Close
1.425
Open
1.42
Last Trade
20
@
1.5
Last Trade Time
Financial Volume
$ 272,284
VWAP
1.4791
Average Volume (3m)
182,815
Shares Outstanding
37,207,799
Dividend Yield
-
PE Ratio
-0.87
Earnings Per Share (EPS)
-1.69
Revenue
5.09M
Net Profit
-62.81M

About Scynexis Inc

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatm... SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Scynexis Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SCYX. The last closing price for Scynexis was $1.43. Over the last year, Scynexis shares have traded in a share price range of $ 1.35 to $ 3.87.

Scynexis currently has 37,207,799 shares outstanding. The market capitalization of Scynexis is $54.70 million. Scynexis has a price to earnings ratio (PE ratio) of -0.87.

SCYX Latest News

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 5)*     SCYNEXIS...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 4)*    ...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*     Scynexis, Inc. (Name of...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 8-K - Current report

0001178253false00011782532024-01-052024-01-05   UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.085.594405594411.431.521.371121141.4098971CS
4-0.19-11.17647058821.71.7481.352169361.51277098CS
12-0.49-24.522.171.351828151.73092043CS
26-0.63-29.43925233642.142.47021.352302981.82972016CS
52-0.13-7.926829268291.643.871.356289352.77380735CS
156-6.5391-81.2401386498.049111.31.154057983.97356758CS
2600.042.721088435371.4711.30.54818423.12610245CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

SCYX Discussion

View Posts
BooDog BooDog 6 months ago
That's a hit. We'll need to see more data for the plan but seems doable.

Glta
👍️0
BooDog BooDog 7 months ago
It couldn't muster through the double top like I was thinking it might.

https://finviz.com/quote.ashx?t=SCYX&p=d
Watching for the consolidation around the 50 dma (2.98). This puppy has been excellent for swing plays.
👍️0
Monksdream Monksdream 7 months ago
SCYX new 52 week high
👍️0
BooDog BooDog 7 months ago
$SCYX 3.80'S, COULD BE TAKEOFF TIME.
👍️0
BooDog BooDog 7 months ago
$SCYX continues to be excellent for swin plays. And excellent for long as well imo.

SCYX chart
👍️0
BooDog BooDog 11 months ago
SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)

Thinking the gap continues to go unfilled.


https://finance.yahoo.com/news/scynexis-reports-closing-exclusive-license-120000142.html
👍️0
subslover subslover 11 months ago
BEAUTIFUL NEWS!!!
SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)
SCYNEXIS is receiving an upfront payment of $90 million with future performance-based milestone payments of up to $503 million and tiered royalties.
GSK obtains the exclusive rights to ibrexafungerp; SCYNEXIS retains rights to all other assets in its proprietary class of enfumafungin-derived antifungal compounds (“fungerps”), currently in preclinical development.
JERSEY CITY, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the closing of its previously announced exclusive license agreement with GSK plc (LSE/NYSE: GSK) to commercialize the novel antifungal BREXAFEMME® (ibrexafungerp tablets) as a treatment for vulvovaginal candidiasis (VVC) and further develop ibrexafungerp for multiple indications in invasive and life-threatening fungal diseases.

Under the terms of the agreement, GSK will make an upfront payment to SCYNEXIS of $90 million, plus additional potential milestone-based payments totaling up to $503 million. GSK will also pay mid-single digit to mid-teen digit tiered royalties on the totality of sales across all indications. Further information regarding the financial terms of the agreement can be found in SCYNEXIS’s SEC filings.

GSK has the rights to develop ibrexafungerp and commercialize BREXAFEMME in all countries except the greater China region and certain other countries already out-licensed by SCYNEXIS to third parties. Under the license agreement, SCYNEXIS will continue executing the Phase 3 program for invasive candidiasis (IC) and other ongoing trials.

SCYNEXIS retains rights to all other assets in its proprietary class of enfumafungin-derived antifungal compounds (“fungerps”), which are currently in preclinical development for the treatment of life-threating invasive fungal diseases. As part of this exclusive license agreement, GSK has been granted a right of first negotiation to these compounds.

About BREXAFEMME® (ibrexafungerp tablets)

BREXAFEMME® (ibrexafungerp tablets) is a novel oral glucan synthase inhibitor with a broad spectrum of activity including against emerging resistant threats. Its mechanism of action is similar to echinocandins, with fungicidal action against yeast (meaning it kills the fungus), versus fluconazole which is fungistatic (meaning it inhibits fungal growth). It was first approved in the U.S. in 2021 for the treatment of VVC and is the first and only oral antifungal approved for both the treatment of VVC and the reduction of the incidence of RVVC. BREXAFEMME has proven activity against WHO-designated priority fungal pathogens such as Candida albicans. In addition, ibrexafungerp has shown activity against Candida auris, another WHO-designated priority fungal pathogen.

Prescribing information is available here.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing its proprietary class of enfumafungin-derived antifungal compounds (“fungerps") as broad-spectrum, systemic antifungal agents for multiple fungal indications. The U.S. Food and Drug Administration (FDA) approved the first representative of this antifungal class, BREXAFEMME® (ibrexafungerp tablets), in June 2021 for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022 for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections is ongoing. Additional assets in the novel “fungerp” class of antifungals are currently in pre-clinical and discovery phase, including the compound SCY-247. For more information, visit www.scynexis.com.

Forward-Looking Statements

Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, including in each case under the caption "Risk Factors," and in other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

Media Relations
Debbie Etchison
SCYNEXIS
debbie.etchison@scynexis.com

https://www.globenewswire.com/newsroom/ti?nf=ODgzODI5MyM1NTkwODMyIzUwMDA3MDcxOA==
https://ml.globenewswire.com/media/YjcwZDJjYWItNmM3Mi00ZTI5LWIxODgtZGY2Y2RhMTYwYWE4LTUwMDA3MDcxOA==/tiny/Scynexis-.png

Source: Scynexis
© 2023 GlobeNewswire, Inc.
👍️0
tw0122 tw0122 11 months ago
Let’s go
👍️0
BooDog BooDog 11 months ago
Only my mouth is watering watching for the gap to fill. short term double bottom @ 2.80. I'm thinking we see lower (very short term). Not sure how long the dip will last.



bullish longer term.

Golden cross came thru end of April.

Message in reply to:
Gap fills in the 1.8's, golden cross around 2.13 - 2.20....

All kinds of things going on here!!!

https://finviz.com/quote.ashx?t=SCYX&p=d

Decent float as well so if anything major happens this is heading towards $10 imo. Wouldn't mind loading up on some cheapies again if / before it does. smile
👍️0
BooDog BooDog 11 months ago
Gap fills in the 1.8's, golden cross around 2.13 - 2.20....

All kinds of things going on here!!!

https://finviz.com/quote.ashx?t=SCYX&p=d

Decent float as well so if anything major happens this is heading towards $10 imo. Wouldn't mind loading up on some cheapies again if / before it does.
👍️0
BooDog BooDog 12 months ago
Buy orders getting triggered. Just watch the LII's. MM's know this puppy is gearing up for a major move. Just one question remains, does the gap around $1.80 go unfilled? Or does it fill. Gaps do go unfiled, as rare as it may seem.

My alerts are set. Ready for the $5 move as well.

All MY opinion of course.
👍️0
duderaja duderaja 12 months ago
Placed a buy order at 3.39 and took my dog out and what do you know it dipped to 3.37 and now back up to 3.7. Looking good here and I believe we will see 5 before long.
👍️0
duderaja duderaja 12 months ago
Check this out:
https://www.benzinga.com/quote/SCYX/analyst-ratings
👍️0
Invest-in-America Invest-in-America 12 months ago
SCYX: Hey, THANKS, Capt. S-L!!! (& best of luck over here, too!!)
👍️0
subslover subslover 12 months ago
You are doing great my friend! Sweet find.
👍️0
Invest-in-America Invest-in-America 12 months ago
SCYX: THANKS, Capt. S-L!!!
👍️0
subslover subslover 12 months ago
NEWS
SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
SCYNEXIS announced it has signed an exclusive agreement with GSK to commercialize and further develop BREXAFEMME® (ibrexafungerp tablets) for all indications. GSK will make an upfront payment to SCYNEXIS of $90 million, as well as potential future milestones and tiered royalties.
SCYNEXIS retains rights to all other assets in the novel “fungerp” antifungal class, including SCY-247, currently in preclinical investigation, with GSK having a right of first negotiation to these preclinical and discovery stage compounds.
Enrollment is complete in the FURI and CARES Phase 3 trials of ibrexafungerp to fight serious drug-resistant refractory invasive fungal infections and in the SCYNERGIA Phase 2 trial of ibrexafungerp in invasive aspergillosis.
SCYNEXIS ended Q4 2022 with cash, cash equivalents and short-term investments of $73.5 million, and upon closure of the GSK transaction and receipt of the upfront payment of $90 million, will have a projected cash runway of more than two years.
JERSEY CITY, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the fourth quarter and full year ended on December 31, 2022.

“We are thrilled to partner with GSK, a leading global organization in the fight against infectious diseases, an area of increasing public health urgency,” said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. “For SCYNEXIS and our shareholders, this deal is transformational and creates significant value, both strengthening our balance sheet and enhancing the opportunity to deliver additional innovative therapies to patients with unmet needs. We will continue advancing ibrexafungerp clinical programs and are in a strong financial position to execute our strategic priorities this year and beyond. With our good track record of efficiently bringing to market first-in-class compounds and the additional resources on hand, our organization is well positioned to continue developing groundbreaking therapies, including our next generation fungerp SCY-247.”

BREXAFEMME Commercial Updates

BREXAFEMME net sales were $1.4 million in Q4 2022 and $5.0 million in 2022. According to IQVIA data, there were 5,125 total prescriptions for BREXAFEMME written in Q4 2022, and more than 20,000 total prescriptions written in 2022.
BREXAFEMME was prescribed by approximately 2,546 individual healthcare professionals (HCPs) in Q4, an increase of 2% over Q3 2022, highlighting the persistence of the prescriber base even in the absence of personal promotion.
Ibrexafungerp Clinical and Regulatory Updates

SCYNEXIS announced U.S. Food and Drug Administration (FDA) approval of a supplemental NDA for a second indication for BREXAFEMME for the reduction in incidence of recurrent vulvovaginal candidiasis (RVVC). The approval was based on positive results from the pivotal Phase 3 CANDLE study reported in February 2022. BREXAFEMME is the first and only FDA-approved therapy for both the treatment of VVC and the reduction in the incidence of RVVC.
Enrollment continues for the MARIO trial, a global Phase 3 study to evaluate ibrexafungerp as an oral step-down treatment for invasive candidiasis (IC) in the hospital setting. Additional sites are being opened globally.
Enrollment is complete in the FURI and CARES Phase 3 trials evaluating ibrexafungerp as salvage therapy in refractory invasive fungal infections, including candidiasis, aspergillosis and other severe fungal infections.
SCYNEXIS received Innovation Passport Designation from the United Kingdom (U.K.) Medicines and Healthcare Products Regulatory Agency (MHRA) for ibrexafungerp for the treatment of IC. The Innovation Passport is the first step and point of entry into the U.K.’s Innovative Licensing and Access Pathway (ILAP), designed to accelerate time to market and facilitate patient access to critical medicines. Innovation Passport designation is awarded to companies developing therapies that have the potential to provide significant benefits to patients with life-threatening or severely debilitating conditions where there is a significant patient or public health need.
Enrollment continues in VANQUISH, a Phase 3b, open-label, multicenter study to evaluate the efficacy, safety and tolerability of oral ibrexafungerp as a treatment for VVC in patients who have failed treatment with fluconazole, based on mycological and clinical outcomes.
Enrollment is complete for the SCYNERGIA Phase 2 study evaluating the safety and efficacy of ibrexafungerp co-administered with voriconazole in patients with invasive pulmonary aspergillosis.
Ibrexafungerp Scientific Presentations and Publications

Publication of an article in the Journal of Fungi in October 2022 highlighting the potential use of ibrexafungerp as a novel treatment option for invasive infections caused by opportunistic molds. The article emphasizes ibrexafungerp’s advantages versus available antifungal drugs, including its oral bioavailability and its broad-spectrum activity against various fungal pathogens, including azole-resistant Aspergillus species. Data from preclinical and clinical studies showcased in the article provide rationale for the continued development of ibrexafungerp as a potential treatment for invasive fungal and mold infections.
Peer-reviewed publication of positive results from a pooled analysis of two Phase 3 studies (VANISH-303 and VANISH-306) in the Journal of Women’s Health in October 2022. Clinical cure rates, in the pooled analysis, were statistically significantly greater for ibrexafungerp when compared with placebo (p < 0.0001). In the pooled analysis, patients receiving ibrexafungerp experienced significantly higher rates of clinical improvement, complete symptom resolution, and mycological cure compared to placebo (all p < 0.0001). Ibrexafungerp demonstrated efficacy in important patient sub-populations, characterized by race, body mass index, symptom severity, and Candida species infection. Ibrexafungerp was well-tolerated in the pooled analysis.
Presented cumulative interim outcomes and all-cause mortality data in patients with refractory candidiasis treated with oral ibrexafungerp from the ongoing Phase 3 FURI study. The analyses were presented during IDWeek 2022 held in Washington, D.C., October 19-23, 2022. Presentations included a platform overview of a cumulative interim analysis of 113 patients enrolled in the ongoing FURI Phase 3 study who had a variety of serious fungal infections, demonstrating 82.3% positive clinical outcomes in patients treated with ibrexafungerp. In addition, the poster highlighted all-cause mortality outcomes through 30 days post completion of ibrexafungerp treatment in 56 patients from the ongoing FURI study who had a diagnosis of invasive candidiasis or candidemia, demonstrating 94.6% overall survival.
Corporate Developments

On March 30, 2023, SCYNEXIS announced that it has entered into an exclusive agreement with GSK to commercialize and further develop BREXAFEMME (ibrexafungerp) for all indications. Under the terms of the license agreement, upon deal close SCYNEXIS will receive an upfront payment of $90 million. The deal is expected to close in the second quarter of 2023. SCYNEXIS will receive tiered royalties on cumulative net sales, and is also eligible to receive potential milestone-based payments totaling $503 million, including: Regulatory approval milestone payments of up to $70 million.Commercial milestone payments of up to $115 million based on first commercial sale in invasive candidiasis (U.S./EU).Sales milestone payments of up to $242.5 million based on annual net sales, with a total of $77.5 million to be paid upon achievement of multiple thresholds up through $200 million; a total of $65 million to be paid upon achievement of multiple thresholds between $300 million and $500 million; and $50 million to be paid at each threshold of $750 million and $1 billion. SCYNEXIS will be responsible for the execution and costs of the ongoing clinical studies of ibrexafungerp and will have the potential to receive up to $75.5 million in success-based development milestones, which are comprised of up to $65 million for the achievement of three interim milestones associated with SCYNEXIS’s continued performance of the ongoing MARIO Study and $10.5 million for the successful completion of the MARIO Study.SCYNEXIS retains rights to all other assets in the novel “fungerp” antifungal class. As part of this exclusive license agreement, GSK has been granted a right of first negotiation to these compounds.This agreement is conditional upon customary conditions including review by the appropriate regulatory agencies under the Hart-Scott-Rodino Act.
On March 30, 2023, SCYNEXIS announced that it entered into an amendment of its previously reported Term Loan Agreement with Hercules Capital/SVB, pursuant to which SCYNEXIS will prepay in full all amounts owed. The payment will be made in Q2 2023.
In November 2022, SCYNEXIS announced that researchers from Case Western Reserve University in Cleveland were awarded a competitive research grant of more than $3 million by the National Institutes of Health (NIH), to investigate a second generation fungerp (SCY-247) developed by SCYNEXIS as a potential treatment for C. auris, a multidrug-resistant yeast that causes serious and often deadly infections.
On December 31, 2022, Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, retired after more than seven years leading the Company.
David Angulo, M.D., became President and Chief Executive Officer of SCYNEXIS and joined the Board of Directors effective January 1, 2023.
In October 2022, Ivor Macleod joined SCYNEXIS as Chief Financial Officer.
Fourth Quarter 2022 Financial Results

BREXAFEMME net product revenues increased to $1.4 million in Q4 2022, from $0.6 million in Q4 2021.

Cost of product revenue was $0.2 million in Q4 2022, compared to $0.2 million in Q4 2021.

Research and development expense for Q4 2022 was $7.8 million, compared to $7.7 million for Q4 2021.

Selling, General & administrative (SG&A) expenses for Q4 2022 increased to $16.0 million from $15.0 million for Q4 2021.

Total other income was $8.1 million for Q4 2022, versus total expense of $6.9 million for Q4 2021. During Q4 2022 and Q4 2021, SCYNEXIS recognized a non-cash gain of $9.1 million and a non-cash loss of $5.0 million, respectively, on the fair value adjustment of the warrant liabilities.

Net loss for Q4 2022 was $14.4 million, or $0.30 basic loss per share, compared to a net loss of $29.2 million, or $1.05 basic loss per share for Q4 2021.

Full Year 2022 Financial Results

BREXAFEMME generated net product revenue of $5.0 million for the full year 2022, compared to $1.1 million for the full year 2021.

Cost of product revenue was $0.6 million for the full year 2022 compared to $0.3 million for the full year 2021.

Research and development expense for the full year 2022 increased to $27.3 million from $23.8 million versus the comparable prior year. The increase of $3.5 million, or 14.7%, was primarily driven by an increase of $3.0 million in clinical development expense, an increase of $1.0 million in preclinical expense, an increase of $0.5 million in both salary and stock compensation expense, offset by a decrease of $1.3 million in chemistry, manufacturing, and controls (CMC) expense, and a $0.2 million decrease in other research and development expense.

SG&A expense for the full year 2022 increased to $63.0 million from $49.9 million versus the comparable prior year. The increase of $13.0 million, or 26.1%, was primarily driven by a $8.6 million increase in commercial related expense, an increase of $1.6 million in salary and payroll related costs, and an increase of $1.5 million in professional fees, all primarily due to the costs recognized to support the commercialization of BREXAFEMME, an increase of $1.0 million in stock compensation expense, and an increase of $1.9 million in severance expense associated with the reduction in work force, offset in part by a decrease of $0.9 million in medical affairs expense and a $0.7 million decrease in business development expense due to the Hansoh license agreement entered into in 2021.

Total other income was $18.2 million for the full year 2022, versus $24.9 million for the comparable prior year. During the full years 2022 and 2021, SCYNEXIS recognized a non-cash gain of $22.3 million and a non-cash gain of $30.4 million, respectively, on the fair value adjustment of the warrant liabilities and non-cash gains of $1.3 million and $1.2 million, respectively, on the fair value adjustment of derivative liabilities.

Net loss for the full year 2022, was $62.8 million, or $1.47 per share, compared to net loss of $32.9 million, or $1.25 per share for the comparable prior year.

Cash Balance

Cash, cash equivalents and short-term investments totaled $73.5 million on December 31, 2022, compared to $104.5 million in cash and cash equivalents on December 31, 2021. Upon closure of the GSK transaction and receipt of the upfront payment of $90 million, based on its current projections, SCYNEXIS will have a cash runway of more than two years.

About Ibrexafungerp

Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. This agent combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations. Ibrexafungerp is in late-stage investigation and development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients. It has demonstrated broad-spectrum antifungal activity, in vitro and in vivo, against multidrug-resistant pathogens, including azole- and echinocandin-resistant strains. The FDA granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for the oral and IV formulations of ibrexafungerp for the indications of invasive candidiasis (IC), including candidemia, and invasive aspergillosis (IA) and has granted Orphan Drug Designation for the IC and IA indications. The European Medicines Agency (EMA) has granted ibrexafungerp Orphan Medicinal Product designation for the indication of IC. Ibrexafungerp is formerly known as SCY-078.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing its lead asset, ibrexafungerp, as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME® (ibrexafungerp tablets) in June 2021, for treatment of vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. Additional assets in the novel “fungerp” antifungal class are currently in preclinical and discovery phase, including the compound SCY-247. For more information, visit www.scynexis.com.

Forward-Looking Statements

Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: SCYNEXIS’s expectation that it will have a cash runway of more than two years. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 31, 2023, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

Media Relations
Debbie Etchison
SCYNEXIS
debbie.etchison@scynexis.com



SCYNEXIS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)

Years Ended December 31,
2022 2021
Revenue:
Product revenue, net $ 4,988 $ 1,113
License agreement revenue 103 12,050
Total revenue 5,091 13,163
Operating expenses:
Cost of product revenue 628 312
Research and development 27,259 23,773
Selling, general and administrative 62,961 49,916
Total operating expenses 90,848 74,001
Loss from operations (85,757 ) (60,838 )
Other (income) expense:
Loss on extinguishment of debt — 2,725
Amortization of debt issuance costs and discount 1,589 1,303
Interest income (1,415 ) (24 )
Interest expense 5,198 2,660
Other income (3 ) (13 )
Warrant liabilities fair value adjustment (22,301 ) (30,365 )
Derivative liability fair value adjustment (1,316 ) (1,170 )
Total other income (18,248 ) (24,884 )
Loss before taxes (67,509 ) (35,954 )
Income tax benefit 4,700 3,088
Net loss $ (62,809 ) $ (32,866 )
Net loss per share – basic and diluted $ (1.47 ) $ (1.25 )
Weighted average common shares outstanding – basic and diluted 42,613,510 26,384,713
👍️0
duderaja duderaja 12 months ago
More upgrades coming.
👍️0
BooDog BooDog 12 months ago
SCYNEXIS, Maxim Raises Price Target To $10, GSK Comes In For Novel Antifungal Agent Ibrexafungerp; Shares Move Higher
👍️0
BooDog BooDog 12 months ago
GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio Bucks

https://finance.yahoo.com/news/gsk-bets-scynexis-fda-approved-171257780.html
👍️0
Invest-in-America Invest-in-America 12 months ago
SCYX: Well, at least I'm BANKING over here!!
👍️0
BooDog BooDog 12 months ago
GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection


https://finance.yahoo.com/news/gsk-scynexis-announce-exclusive-agreement-110500617.html


Booyah
👍️0
Invest-in-America Invest-in-America 12 months ago
FUNNY!!! (I was just being my silly, childish, self!! Heck, I'm only 12, for God's sake!! See my iHub PROFILE!!)
👍️0
subslover subslover 12 months ago
Heard that your knee deep in fungi lol
👍️0
BooDog BooDog 1 year ago
10-K next week probably. Nice reset. See where this settles.
👍️0
murocman murocman 1 year ago
Q4 and annual earnings should be due within a week or so, correct?

Murocman
👍️0
enthalpy enthalpy 1 year ago
I like this play.
👍️0
Invest-in-America Invest-in-America 1 year ago
SCYX: Hey, THANKS for that link!! WOW!! (I need that stuff, too!!!)
👍️0
BooDog BooDog 1 year ago
Anti-Fungal Stocks Rally Following CDC Fungus Study -- Market Talk
6:07 pm ET March 21, 2023 (Dow Jones) Print
18:07 ET - Cantor Fitzgerald says it's time to take a look at two antifungal stocks in light of a study from the Centers for Disease Control and Prevention yesterday describing a rare and often deadly fungus spreading rapidly across the US. Candida auris, a fungus discovered about 15 years ago in Japan, infected at least 2,377 people in the US in 2022, up from 53 in 2016, the CDC says. Cantor analysts reiterate their overweight ratings for Cidara Therapeutics and Scynexis with price targets of $5 and $15, respectively. The analysts say they believe both of these companies have potentially positive catalysts in the next 12 to 18 months. Cidara makes Rezafungin and Scynexis makes Ibrexafungerp, and both drugs are designed to fight fungal infections. Cidara shares closed up nearly 12% to $1.98 and Scynexis surged 35% to $1.56. (patrick.sheridan@wsj.com)


(END) Dow Jones Newswires

March 21, 2023 18:07 ET (22:07 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
👍️0
BooDog BooDog 1 year ago
Trimmed a few here 2.08. Looking good though!!
👍️0
Invest-in-America Invest-in-America 1 year ago
SCYX: Running this morn.????
👍️0
BooDog BooDog 1 year ago
1.70's pm
👍️0
BooDog BooDog 1 year ago
SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis


https://finance.yahoo.com/news/scynexis-announces-fda-approval-second-130000442.html


Thinking this puppy plays well into next summer.
👍️0
BooDog BooDog 1 year ago
SCYNEXIS, Inc.Novel Anti-Infective Treatments


https://www.scynexis.com/pipeline



https://www.scynexis.com/?_sc_token=v2%253ArCFB5M7kDhF0DendplAumDfp0mLJQmmPjXibbF655Pwpp8L8St9zJ5JWXuLRyKtUtDU3NLAry760CeTu07jPC2-7zJNvjIcdmALhP5-txfDhpy-ro8W8Uv93cVU_P05u-1Nm3Y4zfahqmFmswTq5LuZmc2e1aC9Ss1Nnefn-7ep8OcQJeNtAIyo0DvbfqJpL


https://finviz.com/quote.ashx?t=SCYX&p=d

Price history...
https://www.dividendinvestor.com/dividend-news/?symbol=scyx
👍️0
BooDog BooDog 1 year ago
Looking better than I thought. See how this puppy plays into 1st half 2023.
👍️0
BooDog BooDog 1 year ago
Lol. Out 2.19. Paid for dinner.
👍️0
BooDog BooDog 1 year ago
Pushing on up!
👍️0
GMA13 GMA13 2 years ago
RE: THE WEBLINK BELOW:
• Maybe sales for VVC have finally materially increased.
• Announced last week, Phase 3 CARES study showed 78% of patients showed complete or partial response, 11% had stable disease, one patient died of other causes, and one outcome was indeterminate. This is incredible for infections caused by Candida auris.


https://finance.yahoo.com/news/ceo-president-director-scynexis-inc-125539125.html
👍️0
GMA13 GMA13 2 years ago
Today, I emailed Irina of SCYX - IR & recommended that Marco Taglietti, M.D. launch a positive, enthusiastic & aggressive PR campaign ASAP, using many user experiences with their side effects, etc. SCYX should also comment on serious side effects, especially if these type of reactions are the (unfortunate) result of very serious rVVR infections.
I attached the WebMD web link below regarding the revues by the cohort of 7.

Irina thanked me & advised that she would forward my recommendations to SCYX executive management.

?? GLTAL


https://www.webmd.com/drugs/drugreview-181690-brexafemme-oral
👍️0
GMA13 GMA13 2 years ago
$SCYX WebMD has 7 rVVC patient reviews that averaged a 4 out of 5 ??s score, after using Brexafemme. Seems positive, however horrible side effects like serious diarrhea & or vomiting were experienced by almost 30% of the users!
Let’s hope these side effects don’t permanently discourage use.
Opinions are welcome!
?? - GLTAL
👍️0
stox777 stox777 2 years ago
Launch in a few weeks. Reps are being hired with a start date of Feb 7th.
👍️0
351stang 351stang 2 years ago
anyone have any projections for this stock for the next year
👍️0
conix conix 3 years ago
Another chart

👍️0
conix conix 3 years ago
SCYX Chart

👍️0
NoobyDoo NoobyDoo 3 years ago
Today is the day! Please no delay on PDUFA decision. Nice pre-market action, it's going to be an interesting 24 hours - good luck longs $$$
👍️0
NoobyDoo NoobyDoo 3 years ago
A blessed Memorial Day for all that have served and given their lives for our country - thank you!
Tomorrow's PDUFA day! Here's to no delay and everyone's success! Been a long time coming, we're at the one yard line about to take it in for the score! $15-$20 not out of the cards tomorrow, and given some time much higher!
👍️0
Run22222 Run22222 3 years ago
SCYX - SCYNEXIS
👍️0
GMA13 GMA13 3 years ago
So exciting -> IMO the After Hrs plunge yesterday is probably because of nervousness about the Shelf Filing which is standard procedure especially after the execution of a big Offering for Shares & Warrants.
I added more Shares at $6.96 & $7.02.
👍️0
GMA13 GMA13 3 years ago
We are sitting on a potentially a gold mine for the following reasons.

1. There is only one other product (fluconazole) & it is grossly & materially inferior to ibrexafungerp!

•NOTEWORTHY: Vaginal yeast infections are very common in women. It's estimated that 75% of all women will have at least one in their lifetime, and 40%-45% will have multiple cases.

2. Other successful pipeline uses for multiple serious fungal infections may make SCYX the gold standard for Hospital & Outpatient uses.

GLTAL & HAPPY NEW YEAR
👍️0
mr2d2 mr2d2 3 years ago
Insiders started loading this one up on 12/21!
👍️0

Your Recent History

Delayed Upgrade Clock